Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf061 ↗Kurz gefasst
Fallbericht in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Simon F Roy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Nevus, Pigmented, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Melanoma Research Alliance, Fonds de Recherche du Québec en Santé, National Cancer Institute at the National Institutes of Health.
Abstract (Originalsprache)
Background
Large and giant congenital melanocytic naevi (CMN) present a risk for developing melanoma or neurocutaneous melanosis. Most CMN are caused by NRAS or, less commonly, BRAF mutations.
Objectives
To present a series of patients with large-to-giant CMN with BRAF fusion genes as driver alterations and describe their unique clinical presentation.
Methods
We retrospectively identified five patients, from three academic institutions, with giant CMN harbouring BRAF fusion genes. We analysed tumour DNA using capture-based next-generation sequencing.
Results
Four of five patients with giant CMN harbouring a BRAF fusion gene exhibited thousands of satellite naevi, many with significant pruritus, nodularity and firmness. One patient developed neurocutaneous melanosis. Histopathology showed marked stromal desmoplasia, akin to the changes observed in acquired melanocytic naevi with BRAF fusion genes. Notably, one patient responded to the MEK inhibitor trametinib, demonstrating the potential therapeutic advantage of genetic characterization of these lesions.
Conclusions
CMN with BRAF fusion genes appear to have unique clinical features and may be associated with numerous satellite lesions. Marked desmoplasia is a histopathological feature that can point to an underlying BRAF fusion gene.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
- North Dallas Dermatology Associates, Dallas, TX, USA.
- Dermpath Diagnostics New York, White Plains, NY, USA.
- Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
- Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Department of Dermatology, University of Texas Southwestern, Dallas, TX, USA.
ORCID-Profile: Iwei Yeh
Förderung
- Melanoma Research Alliance
- Fonds de Recherche du Québec en Santé
- National Cancer Institute at the National Institutes of Health
- Canadian Institute of Health Research
- NCI NIH HHS
Zitieren
APA
Roy, S. F., Agim, N. G., Mir, A., Couts, K. L., Vandergriff, T., Robinson, W. A., Bastian, B. C., Frieden, I. J., & Yeh, I. (2025). Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf061
Vancouver
Roy SF, Agim NG, Mir A, Couts KL, Vandergriff T, Robinson WA, et al. Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf061
BibTeX
@article{Roy2025,
author = {Roy, Simon F and Agim, Nnenna G and Mir, Adnan and Couts, Kasey L and Vandergriff, Travis and Robinson, William A and Bastian, Boris C and Frieden, Ilona J and Yeh, Iwei},
title = {Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf061}
}
EUVIMED